BioNTech SE (22UAy)

158.05
+4.25(+2.76%)
  • Volume:
    61,244
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    154.85 - 160.10

22UAy Overview

Prev. Close
153.8
Day's Range
154.85-160.1
Revenue
21.19B
Open
157.25
52 wk Range
111.3-332.6
EPS
48.1
Volume
61,244
Market Cap
38.12B
Dividend (Yield)
1.5498
(0.98%)
Average Vol. (3m)
96,684
P/E Ratio
-
Beta
-0.076
1-Year Change
-57.04%
Shares Outstanding
243,019,216
Next Earnings Date
Nov 07, 2022
What is your sentiment on BioNTech?
or
Market is currently closed. Voting is open during market hours.

BioNTech SE News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

BioNTech SE Analysis

BioNTech SE Company Profile

BioNTech SE Company Profile

Employees
3082
  • Type:Equity
  • Market:Germany
  • ISIN:US09075V1026
  • WKN:A2PSR2

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuySellSellBuy
Technical IndicatorsSellStrong BuyStrong BuyStrong SellBuy
SummaryNeutralStrong BuyNeutralStrong SellBuy
  • why us it tanking
    0
    • nice let's break th 20 dollars down mark
      1
      • people are getting severely crushed not only with bntx with almost everything
        0
        • looks like 150
          1
          • I dont think so
            0
          • Alper Drnlooks like 150
            0
        • holy I went from disgust that I sold on Friday to I don't get the 15 dollar turn the wrong way
          0
          • can someone elaborate on why bntx is up today nicely while moderna and nocanax are significantly negative
            0
            • Maybe because they are optimistic about Biontech earnings / financial reports for Monday (8 August)  Especially when they saw Moderna's good earnings.
              0
          • ok looks like bntx could be worth holding for a little bit how do you feel about the three vaccine stocks
            0
            • crazy I got in and got out four days ago along with moderna novanax was a big loss
              0
              • here is why it is tanking because I bought 25 shares I am the kiss of death
                0
                • It looks like the world is about to dive further into turmoil with a new wave of covid coupled with recession and panic
                  0